Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Collagen-PVP vs Pirfenidone in Moderate to Severe COVID-19
NCT06585319Phase 3Completed
- Sponsor
- Hospital Materno Perinatal Mónica Pretelini Sáenz
- Start
- Feb 2020
- Primary completion
- Jun 2021
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of collagen-polyvinylpyrrolidone, pirfenidone in coronavirus disease 2019 (COVID-19), sponsored by Hospital Materno Perinatal Mónica Pretelini Sáenz. Started Feb 2020; status: completed.
02
Drugs
collagen-polyvinylpyrrolidonepirfenidone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06585319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585319.